Eisai expands U.S. ops with $3.9B MGI buyout

A little over a week after announcing that it would explore its "strategic alternatives," MGI Pharma announced that Japan's Eisai had agreed to buy the company for $3.9 billion, a 23 percent premium over the December 7 close. For Eisai, which will lose patent protection for its bestselling drug Aricept in 2010, the news marked the latest in a string of oncology deals, including the $325 million acquisition of Morphotek in April. Earlier, Eisai also paid $205 million for four oncology therapies from Ligand Pharmaceutical.

MGI's two biggest sellers are Dacogen and Aloxi. The biotech has 10 development programs underway for everything from preclinical therapeutics to late-stage studies on approved medications. One of the winners in today's announcement: Carl Icahn, who snapped up $17.8 million in MGI shares even as one analyst was downgrading the biotech. For Eisai, it's another big stride into the U.S., where it is building a new research and development center.

- see this release
- read the report from the Wall Street Journal

ALSO: Adams Respiratory Therapeutics is being acquired by the Reckitt Benckiser Group for $2.3 billion. Release

Related Articles:
Lehman helps MGI study its 'strategic alternatives'. Report
Eisai acquires Morphotek in $325M deal. Report
Eisai plans $105M expansion in NC. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.